Appendix Key contacts & report contributors Americas Regional Leads Bill Barrett Executive Managing Director, <strong>Life</strong> <strong>Sciences</strong>, Americas Richard McBlaine Principal Solution Development, <strong>Life</strong> <strong>Sciences</strong>, Americas Matt Jackson Managing Director, Consulting Shannon Curley Senior Associate, Consulting Howard Rosenberg Executive Director, Solutions Development - Labwell 96 Appendix | <strong>Jones</strong> <strong>Lang</strong> <strong>LaSalle</strong> Brokerage Scot Ginsburg Managing Director, <strong>Life</strong> <strong>Sciences</strong> Brokerage Dan Loughlin Managing Director, <strong>Life</strong> <strong>Sciences</strong> Brokerage Greg O’Brien CEO of Brokerage, Americas Chad Urie Executive Vice President, <strong>Life</strong> <strong>Sciences</strong> Brokerage Research Erin Bovee Research Lead, <strong>Life</strong> <strong>Sciences</strong>, Americas Ben Breslau Managing Director, Americas Research <strong>Global</strong> county statistics definitions & sources* 1 Expenditures for research and development are current and capital expenditures (both public and private) on creative work undertaken systematically to increase knowledge, including knowledge of humanity, culture, and society, and the use of knowledge for new applications. R&D covers basic research, applied research, and experimental development. Source: World Bank 2 Researchers in R&D are professionals engaged in the conception or creation of new knowledge, products, processes, methods, or systems and in the management of the projects concerned. Postgraduate PhD students engaged in R&D are included. Source: World Bank EMEA Regional Leads Charles Tillet Sector Lead, <strong>Life</strong> <strong>Sciences</strong>, EMEA Randall White Director, <strong>Life</strong> <strong>Sciences</strong>, EMEA Research Tom Carroll Research Lead, <strong>Life</strong> <strong>Sciences</strong>, EMEA Asia Pacific Regional Lead David Wilton Regional Director, Head of Industrial, Asia Pacific Research Anne Thoraval Head of Corporate Research, Asia Pacific Jane Murray Head, Asia Pacific Research 3 High-technology exports are products with high R&D intensity, such as in aerospace, computers, pharmaceuticals, scientific instruments, and electrical machinery. Source: World Bank 4 Total health expenditure is the sum of public and private health expenditure. Source: World Bank 5 Overall Innovation capabilities includes: capacity for innovation, quality of scientific research institutions, company spending on R&D, universityindustry collaboration in R&D, government procurement of advances tech products, availability of scientists and engineers and utility patents granted per million people. Source: The World Economic Forum’s <strong>Global</strong> Competitiveness Index <strong>2011</strong>-2012 * For United States statistic sources, please refer to the United States methodology on page 16 Tof C
www.joneslanglasalle.com ©<strong>2011</strong> <strong>Jones</strong> <strong>Lang</strong> <strong>LaSalle</strong> IP, Inc. All rights reserved. All information contained herein is from sources deemed reliable; however, no representation or warranty is made to the accuracy thereof. Tof C
- Page 1 and 2:
Life sciences cluster report Global
- Page 3 and 4:
Introduction A message from Bill Ba
- Page 5 and 6:
Revenue growth To increase revenue,
- Page 7 and 8:
= $15 billion 7 The drug and pharma
- Page 9 and 10:
Manufacturing Office R&D HQ Support
- Page 11 and 12:
India ranked third for inward direc
- Page 13 and 14:
Conclusion As we emerge from a peri
- Page 15 and 16:
United States, Canada, Brazil and P
- Page 17 and 18:
4th 13.5% 8th % life science employ
- Page 19 and 20:
Bay Area Innovation capital For mor
- Page 21 and 22:
Boston Others, however, choose to k
- Page 23 and 24:
13th 11.6% 8th % life science emplo
- Page 25 and 26:
Los Angeles Innovation capital The
- Page 27 and 28:
New York / New Jersey in excess of
- Page 29 and 30:
2nd 14.8% 6th % life science employ
- Page 31 and 32:
Philadelphia Innovation capital Wit
- Page 33 and 34:
Raleigh Durham The Raleigh-Durham l
- Page 35 and 36:
11th 11.9% 8th % life science emplo
- Page 37 and 38:
San Diego Innovation capital The Sc
- Page 39 and 40:
Seattle Typically, life sciences te
- Page 41 and 42:
12th 11.7% 3rd % life science emplo
- Page 43 and 44:
Washington DC / Suburban Maryland F
- Page 45 and 46: Atlanta In a 2009 study by Georgia
- Page 47 and 48: 9th 12.3% 5th % life science employ
- Page 49 and 50: 13th 11.6% 7th % life science emplo
- Page 51 and 52: 10th 12.1% % life science employmen
- Page 53 and 54: Florida Industry framework Intellec
- Page 55 and 56: Houston Industry framework Intellec
- Page 57 and 58: 6th 13.0% % life science employment
- Page 59 and 60: Indianapolis In addition, several i
- Page 61 and 62: Minneapolis historically have worke
- Page 63 and 64: Canada Industry framework Intellect
- Page 65 and 66: 1.1% R&D expenditure (% of GDP, 200
- Page 67 and 68: Emerging cluster Puerto Rico Over t
- Page 69 and 70: France, Germany, Switzerland and Un
- Page 71 and 72: France Pharmaceutical production is
- Page 73 and 74: 2.5% R&D expenditure (% of GDP, 200
- Page 75 and 76: 2.9% R&D expenditure (% of GDP, 200
- Page 77 and 78: 1.9% R&D expenditure (% of GDP, 200
- Page 79 and 80: United Kingdom Industry framework T
- Page 81 and 82: 1.4% R&D expenditure (% of GDP, 200
- Page 83 and 84: China ■ Zhongguancun (ZGC) Life S
- Page 85 and 86: India The life sciences industry is
- Page 87 and 88: India To support the distribution c
- Page 89 and 90: Indonesia About 35 companies are fo
- Page 91 and 92: 2.3% R&D expenditure (% of GDP, 200
- Page 93 and 94: Singapore Fiscal & political resour
- Page 95: Emerging cluster governments in Asi
Change language